ORBACTIV Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Orbactiv, and what generic alternatives are available?
Orbactiv is a drug marketed by Melinta Therap and is included in one NDA. There are three patents protecting this drug.
This drug has thirty-nine patent family members in seventeen countries.
The generic ingredient in ORBACTIV is oritavancin diphosphate. One supplier is listed for this compound. Additional details are available on the oritavancin diphosphate profile page.
DrugPatentWatch® Generic Entry Outlook for Orbactiv
Orbactiv was eligible for patent challenges on August 6, 2018.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ORBACTIV?
- What are the global sales for ORBACTIV?
- What is Average Wholesale Price for ORBACTIV?
Summary for ORBACTIV
International Patents: | 39 |
US Patents: | 3 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 27 |
Clinical Trials: | 7 |
Patent Applications: | 25 |
Drug Prices: | Drug price information for ORBACTIV |
What excipients (inactive ingredients) are in ORBACTIV? | ORBACTIV excipients list |
DailyMed Link: | ORBACTIV at DailyMed |
![ORBACTIV drug patent expirations Drug patent expirations by year for ORBACTIV](/p/graph/s/t/ORBACTIV-patent-expirations.png)
![Drug Prices for ORBACTIV](/p/graph/drug-price/ORBACTIV.png)
US Patents and Regulatory Information for ORBACTIV
ORBACTIV is protected by three US patents and two FDA Regulatory Exclusivities.
Patents protecting ORBACTIV
Methods of treatment using single doses of oritavancin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE
High purity oritavancin and method of producing same
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Methods of treating bacterial infections using oritavancin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
FDA Regulatory Exclusivity protecting ORBACTIV
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
GENERATING ANTIBIOTIC INCENTIVES NOW
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ORBACTIV
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | ⤷ Sign Up | ⤷ Sign Up |
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ORBACTIV
See the table below for patents covering ORBACTIV around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 2016011245 | ⤷ Sign Up | |
Spain | 2210274 | ⤷ Sign Up | |
Japan | H07258289 | GLYCOPEPTIDE | ⤷ Sign Up |
Finland | 117095 | ⤷ Sign Up | |
Canada | 2760159 | PROCEDES DE TRAITEMENT D'INFECTIONS BACTERIENNES A L'AIDE D'ORITAVANCINE (METHODS OF TREATING BACTERIAL INFECTIONS USING ORITAVANCIN) | ⤷ Sign Up |
Brazil | 9500365 | ⤷ Sign Up | |
Germany | 69531709 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ORBACTIV
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2337575 | 2016019 | Norway | ⤷ Sign Up | PRODUCT NAME: ORITAVANCIN OG FARMASOEYTISK; REG. NO/DATE: EU/1/15/989 20150415 |
2337575 | CA 2016 00044 | Denmark | ⤷ Sign Up | PRODUCT NAME: ORITAVANCIN OG/ELLER FARMACEUTISKE SALTE HERAF, HERUNDER DIFOSFATSALTE; REG. NO/DATE: EU/1/15/989 20150323 |
2337575 | 2016/040 | Ireland | ⤷ Sign Up | PRODUCT NAME: ORITAVANCIN AND PHARMACEUTICAL SALTS THEREOF, E.G DIPHOSPHATE SALTS; REGISTRATION NO/DATE: EU/1/15/989 20150319 |
2337575 | 1690041-7 | Sweden | ⤷ Sign Up | PRODUCT NAME: ORITAVANCIN ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/15/989 20150323 |
2337575 | 132016000101430 | Italy | ⤷ Sign Up | PRODUCT NAME: ORITAVANCINA E I SUOI SALI DI ADDIZIONE FARMACEUTICAMENTE ACCETTABILI, IN PARTICOLARE IL DIFOSFATO(ORBACTIV); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/989, 20150323 |
2337575 | 122016000075 | Germany | ⤷ Sign Up | PRODUCT NAME: ORITAVANCIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/989 20150319 |
2337575 | 300834 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ORITAVANCIN; REGISTRATION NO/DATE: EU/1/15/989 20150323 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |